Trial Outcomes & Findings for Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain (NCT NCT03848143)
NCT ID: NCT03848143
Last Updated: 2026-07-30
Results Overview
Patient will record the pain intensity by means of a visual analogue scale (VAS, from 0-10 being 0 no pain and 10 the worst possible pain)
COMPLETED
PHASE2
8 participants
Baseline, 3 month follow up
2026-07-30
Participant Flow
Participant milestones
| Measure |
BOTOX
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.
1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).
Each patient will receive 50 U of onabotulinum toxin A.
onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
|
|---|---|
|
Round 1
STARTED
|
8
|
|
Round 1
COMPLETED
|
5
|
|
Round 1
NOT COMPLETED
|
3
|
|
Round 2
STARTED
|
5
|
|
Round 2
COMPLETED
|
3
|
|
Round 2
NOT COMPLETED
|
2
|
Reasons for withdrawal
| Measure |
BOTOX
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.
1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).
Each patient will receive 50 U of onabotulinum toxin A.
onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
|
|---|---|
|
Round 1
Lost to Follow-up
|
2
|
|
Round 1
Lack of Efficacy
|
1
|
|
Round 2
Lost to Follow-up
|
1
|
|
Round 2
Lack of Efficacy
|
1
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
BOTOX
n=8 Participants
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.
1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).
Each patient will receive 50 U of onabotulinum toxin A.
onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
|
|---|---|
|
Age, Continuous
|
55 years
STANDARD_DEVIATION 10.93 • n=8 Participants
|
|
Sex: Female, Male
Female
|
6 Participants
n=8 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=8 Participants
|
|
Region of Enrollment
United States
|
8 participants
n=8 Participants
|
PRIMARY outcome
Timeframe: Baseline, 3 month follow upPopulation: The population analyzed were the participants that completed the first round.
Patient will record the pain intensity by means of a visual analogue scale (VAS, from 0-10 being 0 no pain and 10 the worst possible pain)
Outcome measures
| Measure |
BOTOX
n=5 Participants
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.
1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).
Each patient will receive 50 U of onabotulinum toxin A.
onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
|
|---|---|
|
Change in Pain Intensity (Round 1)
|
3.91 units on a scale
Standard Deviation .86
|
PRIMARY outcome
Timeframe: Baseline, 6 month follow upPopulation: Only 3 participants completed the 6 month follow up questionnaire and provided outcome data; therefore 3 participants were included in this analysis.
Patient will record the pain intensity by means of a visual analogue scale (VAS, from 0-10 being 0 no pain and 10 the worst possible pain)
Outcome measures
| Measure |
BOTOX
n=3 Participants
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.
1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).
Each patient will receive 50 U of onabotulinum toxin A.
onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
|
|---|---|
|
Change in Pain Intensity (Round 2)
|
3.33 units on a scale
Standard Deviation 3.51
|
Adverse Events
BOTOX
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
BOTOX
n=8 participants at risk
Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.
1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).
Each patient will receive 50 U of onabotulinum toxin A.
onabotulinum toxin A: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
|
|---|---|
|
Nervous system disorders
Lip and Cheek Weakness
|
12.5%
1/8 • from enrollment until end of follow-up, up to 6 months
|
|
Nervous system disorders
Lip and Nose Numbness
|
12.5%
1/8 • from enrollment until end of follow-up, up to 6 months
|
|
Nervous system disorders
Facial Asymmetry
|
25.0%
2/8 • from enrollment until end of follow-up, up to 6 months
|
|
Nervous system disorders
Speech Difficulty
|
25.0%
2/8 • from enrollment until end of follow-up, up to 6 months
|
|
Nervous system disorders
Injection Site Pain
|
25.0%
2/8 • from enrollment until end of follow-up, up to 6 months
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place